Who Paid My Doc
Crofab
Drug Anti-Venom
NDC 50633-110-12
General payments
$1,467,657
Research payments
$663,878
Through program year 2024, $1,467,657 in general payments and $663,878 in research payments were reported against Crofab (Anti-Venom).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $387,211 | 202 |
| 2023 | General | $219,457 | 102 |
| 2023 | Research | $64,557 | 1 |
| 2022 | General | $388,078 | 96 |
| 2022 | Research | $55,769 | 3 |
| 2021 | General | $138,518 | 220 |
| 2021 | Research | $188,557 | 3 |
| 2020 | Research | $354,996 | 13 |
| 2019 | General | $334,392 | 832 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.
The top 5 of 23 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 19 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
1,452 general · 20 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.